[俄罗斯及其他欧洲国家心血管高风险患者动脉粥样硬化性疾病一级预防的疗效（第1部分）]
[Efficacy of primary prevention for atherosclerosis-induced diseases in patients with high cardiovascular risk in Russia and other European countries (Part 1)].
作者信息
Boytsov S A, Pogosova N V, Oganov R G, Ausheva A K, Sokolova O Y, Kursakov A A, Pozdnyakov Y M, Gomyranova N V, Karpova A V, Isakova S S, Salbieva A O, Yusubova A I, Lel'chuk I N, Allenov A M, Vinokurov V G, Strelkova S N, Klimova A O, Loshkarev Y V, Rubanov R V
机构信息
State Budgetary Institution of Health Care "National Research Center for Preventive Medicine" of the Ministry of Health of the Russian Federation.
Municipal Clinic #210, Moscow Department of Health Care.
出版信息
Kardiologiia. 2017;57(S1):333-344. doi: 10.18087/cardio.2411.
RELEVANCE
Evaluation of the effectiveness of risk management in persons with high cardiovascular risk is an important element in reducing the death rate of the population from cardiovascular diseases (CVD).
AIM
Analysis of the prevalence and level of risk factors control in patients with high CV risk CVD from the Russian centers of the primary care unit of the EUROASPIRE IV study in comparison with the general population of the study.
MATERIALS AND METHODS
In this cross-sectional study, 14 European countries, including the Russian Federation, participated. Patients aged 18 to 79 years were included in the study, without clinical manifestations of atherosclerosis, who were prescribed antihypertensive therapy and/or lipid lowering therapy and/or treatment for diabetes between the ages of ≥6 months and.
相关性
评估心血管高风险人群风险管理的有效性是降低人群心血管疾病（CVD）死亡率的重要因素。
目的
与该研究的普通人群相比，分析欧洲动脉粥样硬化预防与逆转调查（EUROASPIRE）IV研究俄罗斯基层医疗单位中心的心血管高风险CVD患者的危险因素控制患病率及水平。
材料与方法
在这项横断面研究中，包括俄罗斯联邦在内的14个欧洲国家参与其中。研究纳入年龄在18至79岁之间、无动脉粥样硬化临床表现、在≥6个月期间接受过抗高血压治疗和/或降脂治疗和/或糖尿病治疗的患者。
Zotero 插件